SIR 2024
Arterial Interventions and Peripheral Arterial Disease (PAD)
Alexander Andrew Argame, BSN, RN (he/him/his)
Medical Student
Kaiser Permanente Bernard J. Tyson School of Medicine
Financial relationships: Full list of relationships is listed on the CME information page.
Huma Manjra, BS
Medical Student
Kaiser Permanente School of Medicine
Disclosure information not submitted.
Mohammed AlDajani, BS
Medical Student
Kaiser Permanente School of Medicine
Disclosure information not submitted.
Alok Bhatt, MD
Assistant Program Director of Vascular and Interventional Integrated Residency
Kaiser Permanente physician
Financial relationships: Full list of relationships is listed on the CME information page.
Cardiovascular risk reduction discussion will encompass pharmacotherapy, including:
• Cholesterol management through statin 1 use/considerations/goals and statin alternatives including Ezetimibe,12 PCSK9 Inhibitors,12 and Bempedoic Acid 14
• Glycemic control including GLP1 Receptor Agonists 11 and SGLT2 Inhibitors 10, 21, 22
• Hypertensive management including ACE Inhibitors and ARB’s 2
• Antiplatelet therapy comparing aspirin, P2Y12 ADP inhibitors, and dual-combination therapies 7
• Anticoagulant therapy exploring factor Xa inhibitors 3, 9
• Smoking cessation/counseling 7
• Influenza vaccination 7
Leg symptom improvement discussion will include:
• Role of statins 8
• Cilostazol 5 and contraindications
• Hydration and albumin complement protocol 18 In conclusion, this exhibit will highlight GDMT and updates for claudicants.
• Structured Exercise Therapy comparing/contrasting supervised exercise program vs. structured community- or home-based exercise program,7 while considering alternative strategies including arm ergometry,20 leg cycling,20 resistance training,17 pain-free treadmill training,15 and various exercise intensity levels 6, 13, 16
Conclusion and/or Teaching Points: